Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ephedrine + norepinephrine is a combination of two sympathomimetic agents used primarily as vasopressors to treat hypotension, especially in the setting of anesthesia. Both drugs act on adrenergic receptors but with different profiles: - **Ephedrine** acts as both a direct and indirect sympathomimetic. It directly stimulates alpha- and beta-adrenergic receptors and indirectly increases the release of norepinephrine from sympathetic neurons, leading to increased heart rate, cardiac output, peripheral resistance, and blood pressure. It is also used for bronchial asthma due to its bronchodilator effects[1][3][7][9]. - **Norepinephrine** (also known as noradrenaline) is a potent alpha-adrenergic agonist with some beta activity. Its primary effect is vasoconstriction via stimulation of alpha-1 and alpha-2 adrenergic receptors, resulting in increased systemic vascular resistance and blood pressure[8]. The combination may be considered in clinical settings where rapid correction of hypotension is required or when one agent alone does not achieve adequate hemodynamic response[5]. Both are small molecule drugs administered intravenously.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ephedrine + norepinephrine.